- Oops!Something went wrong.Please try again later.
ORLANDO, Fla., March 23, 2021 (GLOBE NEWSWIRE) -- Medical Technology Disruptor.
Normally, we write our own headlines for the pages of the Emerging Market Report but in this instance there is no finer title than the one that adorns the Company’s homepage. And frankly, it is one of our peak areas of interest.
We’ve been frank about the epic changes that the pandemic has created and our fervent goal to participate in COVID driven trends. There are very few good things about this awful disease but some of the changes in health care for which it has been catalytic are among them. Paramount among them, we believe, will be telehealth and testing enhancements.
As such, let’s take a look at Medivolve Inc. (“Medivolve” or the “Company”) (NEO:MEDV; OTC:COPRF; FRA:4NC)
The company offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.
First, Medivolve and its wholly owned subsidiary, Collection Sites, are developing telehealth plans that include remote patient monitoring and virtual care, among other offerings. Collection Sites is intent on leveraging its network of sites and large customer database to market these new services and launch a series of mobile clinics.
It is worth noting that Collection Sites is launching a nationwide network of testing sites for rapid COVID testing now and which will then evolve into the aforementioned mobile clinics.
We like the now-and-then angle on their business model, this rapid testing system to let people know they are healthy or the actionable alternative. What comes next after this dreadful period is behind us is likely to be better healthcare ecosystem to create a healthier you.
It’s a logical next step in the evolution of health care, driven in part by a Medical Technology Disruptor.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php
Must Read OTC Markets/SEC policy on stock promotion and investor protection
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.
EMC has been paid $250,000 by Medivolve, Inc. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php
Please note that the future impact of COVID is unknown at this time and the ultimate extent of the impact of any epidemic, pandemic, or other health crisis on any business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity, increase, or decrease of such epidemic, pandemic or other health crisis.
Emerging Markets Consulting, LLC
390 North Orange Ave Suite 2300
Orlando, FL 32801